Could GLP-1s Shape the Future of Endometriosis Care?

In this episode, Dr. Shanti Mohling and Dr. Nicholas Fogelson explore one of the most intriguing emerging questions in endometriosis care: could GLP-1 receptor agonists, such as Ozempic and Zepbound, play a role in reducing endometriosis-related symptoms? These medications are not currently FDA-approved for endometriosis, and the evidence is still early. But patient reports, survey data, and basic science raise compelling questions about how GLP-1s may affect inflammation, pain, and the broader systemic nature of endometriosis. Drs. Fogelson and Mohling discuss what is known, what remains speculative, the potential risks, and why a possible non-hormonal approach is worth watching. Highlights: How GLP-1 receptor agonists work beyond blood sugar and weight, including effects on appetite, satiety, reward pathways, the microbiome, and inflammation. Why endometriosis is increasingly understood as a systemic inflammatory disease, not just lesions in the pelvis. Early observations from patients and surveys suggesting some people with endometriosis report symptom improvement while taking GLP-1 medications. The current limits of the evidence, including the lack of randomized trials and the fact that GLP-1s are not medically indicated for endometriosis. Potential risks and side effects, including gastrointestinal symptoms, gastroparesis, gallbladder disease, pancreatitis, muscle loss, and the need for medical supervision. NOTE: Anyone considering GLP-1s should speak with their own physician about potential risks, side effects, and whether they are appropriate. For clinical consultations: contact Northwest Endometriosis and Pelvic Surgery in Portland, OR at (503) 715-1377 or email us at [email protected]  Follow us on Instagram: @Nicholasfogelson and @drshantimohling Download a transcript of this episode.